Updates are available Correction dated 2023-06-03
Click to view Correction: https://0-doi-org.brum.beds.ac.uk/10.1186/s40814-023-01331-0
-
Authors
Gierthmuehlen, Mortimer http://orcid.org/0000-0001-8575-6445
Höffken, Nadine
Timmesfeld, Nina
Schmieder, Kirsten
Reinacher-Schick, Anke
-
Funding
Funding for this research was provided by:
Universitätsklinikum der Ruhr-Universität Bochum
- License Information
-
More Information
Article History
Received: 11 August 2022
Accepted: 30 March 2023
First Online: 22 April 2023
Change Date: 3 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s40814-023-01331-0
Declarations
:
: This investigator-initiated trial has received approval by our local ethics committee of the Ruhr-University Bochum under the number 21–7395 on 28.01.2022 and was registered at the German Trial Registry under DRKS00027481 on 31.01.2022 (ExternalRef removed). Accepted version of the study protocol is 2.0 from 05.12.2021. Sponsor is the University Medical Center Knappschaftskrankenhaus Bochum.
: MG is founder and advisor of the Medtech-startup Neuroloop GmbH, which develops an invasive vagal nerve stimulator against arterial hypertension. The company has no link to this presented study, as the topic (noninvasive vagal nerve stimulation against fatigue) does not interfere with the companies scope (invasive vagal nerve stimulation against hypertension). The other authors declare that they have no competing interests.
